Oncoinvent ASA (OSL:ONCIN)

Total Valuation

Oncoinvent ASA has a market cap or net worth of NOK 136.65 million. The enterprise value is 67.47 million.

Market Cap	136.65M
Enterprise Value	67.47M

Important Dates

The next estimated earnings date is Thursday, November 20, 2025.

Earnings Date	Nov 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncoinvent ASA has 97.74 million shares outstanding. The number of shares has increased by 555.68% in one year.

Current Share Class	97.74M
Shares Outstanding	97.74M
Shares Change (YoY)	+555.68%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	10.21%
Owned by Institutions (%)	20.24%
Float	55.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.83
PB Ratio	1.97
P/TBV Ratio	1.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.63
EV / Sales	3.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.79

Financial Position

The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.09.

Current Ratio	2.61
Quick Ratio	2.61
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.07
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-147.73%
Revenue Per Employee	555,444
Profits Per Employee	-2.96M
Employee Count	34
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	1.44
200-Day Moving Average	1.82
Relative Strength Index (RSI)	50.84
Average Volume (20 Days)	75,256

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncoinvent ASA had revenue of NOK 20.00 million and -106.73 million in losses. Loss per share was -0.84.

Revenue	20.00M
Gross Profit	20.00M
Operating Income	-107.76M
Pretax Income	-106.73M
Net Income	-106.73M
EBITDA	-98.87M
EBIT	-107.76M
Loss Per Share	-0.84

Balance Sheet

The company has 75.39 million in cash and 6.21 million in debt, giving a net cash position of 69.17 million or 0.71 per share.

Cash & Cash Equivalents	75.39M
Total Debt	6.21M
Net Cash	69.17M
Net Cash Per Share	0.71
Equity (Book Value)	69.46M
Book Value Per Share	0.71
Working Capital	50.42M

Cash Flow

In the last 12 months, operating cash flow was -83.80 million and capital expenditures -1.80 million, giving a free cash flow of -85.60 million.

Operating Cash Flow	-83.80M
Capital Expenditures	-1.80M
Free Cash Flow	-85.60M
FCF Per Share	-0.88

Margins

Gross Margin	100.00%
Operating Margin	-538.89%
Pretax Margin	-533.74%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncoinvent ASA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-555.68%
Shareholder Yield	-555.68%
Earnings Yield	-78.11%
FCF Yield	-62.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncoinvent ASA has an Altman Z-Score of -8.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.25
Piotroski F-Score	2